International Urology and Nephrology

, Volume 51, Issue 11, pp 1999–2004 | Cite as

Comparison of double-dose vs. usual dose of nicorandil for the prevention of contrast-induced nephropathy after cardiac catheterization

  • Zhican Zeng
  • XiaoFeng Fu
  • Xue Zhang
  • Naikuan FuEmail author
Nephrology - Original Paper



Contrast-associated nephropathy (CIN), the third main reason of the acute kidney injury (AKI) in inpatients, is a potentially severe side effect of angiography and the preventive role of nicorandil on CIN is still controversal. The aim of this clinical trial was to evaluate the preventive role of different doses of nicorandil on CIN in patients experiencing cardiac catheterization compared with hydration.


We recorded outcomes from 330 patients who were randomly divided to either a double-dose (30 mg/day) nicorandil group or to a usual-dose (15 mg/day) nicorandil group or a control group (hydration only). The primary endpoint of the current research was the occurrence of CIN, which is defined as a relative elevation of SCr level of 25% above the baseline or an absolute increment of SCr of more than 44.2 µmol/L (0.5 mg/dL) within 48 or 72 h after contrast medium exposure. Additional endpoints were the changes in BUN, SCr, Cys-C, eGFR, and CRP level within 48 h after contrast agent exposure and major adverse events occurring during hospitalization and 14 days of follow-up.


6 out of 111 patients (5.4%) had contrast-induced nephropathy in the double-dose group and it occured 11 out of 107 patients (10.3%) in the usual-dose group, 16 out of 112 patients (14.3%) in the control group. There was a significant difference in the occurrence of CIN between the double-dose group and the control group at 48 h after taking the radiocontrast medium (p = 0.026) while no such significant difference observed in the usual-dose group and the control group (p = 0.367), the double-dose group and usual-dose group (p = 0.180) as well.


Daily peri-procedural usual-dose nicorandil could just relieve contrast-induced renal injury, only double-dose nicorandil was associated with a reduced incidence of CI-AKI compared with hydration.


Contrast-induced nephropathy Nicorandil Percutaneous coronary intervention Prevention 



This study was funded by a Grant from the Tianjin Municipal Health and Family Planning Commission (Grant number: 14KG124). We thank all the participants and enrolled patients of Tianjin Medical University in Tianjin of China for their cooperation.

Compliance with ethical standards

Conflict of interest

The authors have no conflict of interest to declare.

Human and animal rights

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all enrolled patients included in the research.


  1. 1.
    Wu MY, Hsiang HF, Wong CS, Yao MS, Li YW, Hsiang CY, Bai CH et al (2013) The effectiveness of N-acetylcysteine in preventing contrast-induced nephropathy in patients undergoing contrast-enhanced computed tomography: a meta-analysis of randomized controlled trials. Int Urol Nephrol 45:1309–1318. CrossRefPubMedGoogle Scholar
  2. 2.
    Kassis HM, Minsinger KD, McCullough PA, Block CA, Sidhu MS, Brown JR (2015) A review of the use of iloprost, a synthetic prostacyclin, in the prevention of radiocontrast nephropathy in patients undergoing coronary angiography and intervention. Clin Cardiol 38:492–498. CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, Singh M et al (2002) Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 105:2259–2264CrossRefGoogle Scholar
  4. 4.
    Su X, Xie X, Liu L, Lv J, Song F, Perkovic V, Zhang H (2017) Comparative effectiveness of 12 treatment strategies for preventing contrast-induced acute kidney injury: a systematic review and Bayesian network meta-analysis. Am J Kidney Dis 69:69–77. CrossRefPubMedGoogle Scholar
  5. 5.
    Gomes VO, Poli DFC, Caramori P, Lasevitch R, Bodanese LC, Araujo A, Roedel AP et al (2005) N-Acetylcysteine does not prevent contrast induced nephropathy after cardiac catheterisation with an ionic low osmolality contrast medium: a multicentre clinical trial. Heart 91:774–778. CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Gu G, Zhang Y, Lu R, Cui W (2015) Additional furosemide treatment beyond saline hydration for the prevention of contrast-induced nephropathy: a meta-analysis of randomized controlled trials. Int J Clin Exp Med 8:387–394PubMedPubMedCentralGoogle Scholar
  7. 7.
    Taira N (1989) Nicorandil as a hybrid between nitrates and potassium channel activators. Am J Cardiol 63:18J–24JCrossRefGoogle Scholar
  8. 8.
    Shimizu S, Saito M, Kinoshita Y, Ohmasa F, Dimitriadis F, Shomori K, Hayashi A et al (2011) Nicorandil ameliorates ischaemia–reperfusion injury in the rat kidney. Br J Pharmacol 163:272–282. CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Sun Z, Zhang X, Ito K, Li Y, Montgomery RA, Tachibana S, Williams GM (2008) Amelioration of oxidative mitochondrial DNA damage and deletion after renal ischemic injury by the KATP channel opener diazoxide. Am J Physiol Ren Physiol 294:F491–F498. CrossRefGoogle Scholar
  10. 10.
    Liu YH, Jiang L, Chen JY, Tan N, Liu Y, He PC (2016) Does N-terminal pro-brain natriuretic peptide add prognostic value to the Mehran risk score for contrast-induced nephropathy and long-term outcomes after primary percutaneous coronary intervention? Int Urol Nephrol 48:1675–1682. CrossRefPubMedGoogle Scholar
  11. 11.
    Iranirad L, Hejazi SF, Sadeghi MS, Jang SA (2017) Efficacy of nicorandil treatment for prevention of contrast-induced nephropathy in high-risk patients undergoing cardiac catheterization: a prospective randomized controlled trial. Cardiol J 24:502–507. CrossRefPubMedGoogle Scholar
  12. 12.
    Quayle JM, Nelson MT, Standen NB (1997) ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol Rev 77:1165–1232. CrossRefPubMedGoogle Scholar
  13. 13.
    Miki T, Seino S (2005) Roles of KATP channels as metabolic sensors in acute metabolic changes. J Mol Cell Cardiol 38:917–925. CrossRefPubMedGoogle Scholar
  14. 14.
    Sato T, Sasaki N, O’Rourke B, Marban E (2000) Nicorandil, a potent cardioprotective agent, acts by opening mitochondrial ATP-dependent potassium channels. J Am Coll Cardiol 35:514–518CrossRefGoogle Scholar
  15. 15.
    Ko YG, Lee BK, Kang WC, Moon JY, Cho YH, Choi SH, Hong MK et al (2013) Preventive effect of pretreatment with intravenous nicorandil on contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography (PRINCIPLE Study). Yonsei Med J 54:957–964. CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Fan Y, Wei Q, Cai J, Shi Y, Zhang Y, Yao L, Wang X et al (2016) Preventive effect of oral nicorandil on contrast-induced nephropathy in patients with renal insufficiency undergoing elective cardiac catheterization. Heart Vessels 31:1776–1782. CrossRefPubMedGoogle Scholar
  17. 17.
    Bei WJ, Chen SQ, Li HL, Wu DX, Duan C, Chen PY, Chen JY et al (2017) Comparing common doses (double-dose vs usual-dose) of atorvastatin for preventing contrast-induced acute kidney injury and mortality after coronary angiography. Medicine (Baltimore) 96:e7501. CrossRefGoogle Scholar
  18. 18.
    Kong DG, Hou YF, Ma LL, Yao DK, Wang LX (2012) Comparison of oral and intravenous hydration strategies for the prevention of contrast-induced nephropathy in patients undergoing coronary angiography or angioplasty: a randomized clinical trial. Acta Cardiol 67:565–569. CrossRefPubMedGoogle Scholar
  19. 19.
    Hiremath S, Akbari A, Shabana W, Fergusson DA, Knoll GA (2013) Prevention of contrast-induced acute kidney injury: is simple oral hydration similar to intravenous? A systematic review of the evidence. PLoS One 8:e60009. CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  • Zhican Zeng
    • 1
  • XiaoFeng Fu
    • 2
  • Xue Zhang
    • 2
  • Naikuan Fu
    • 2
    Email author
  1. 1.Tianjin Medical UniversityTianjinChina
  2. 2.Department of CardiologyTianjin Chest HospitalTianjinChina

Personalised recommendations